CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has [...]
CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]
REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by Circulogene, this pilot [...]
Advanced molecular genetics testing delivers lung cancer treatment decision with 5-day international turnaround. An Israeli oncologist referred his 63-year-old female lung cancer patient to the personalized cancer testing expertise of CIRCULOGENE looking for a faster treatment [...]
Single-tube liquid biopsy overcomes tissue biopsy failure to give oncologist personalized treatment decision guidance in matter of days. A southeastern oncologist treating a 66-year-old male with lung cancer was unable to obtain testing results due [...]
CIRCULOGENE testing rapidly matches young patient with targeted therapy for rare non-small-cell lung cancer genetic variation. An oncologist referred a blood sample on his 44-year-old female non-small cell lung cancer (NSCLC) patient to CIRCULOGENE for [...]
Publication: ACTA Scientific Cancer Biology Volume 2 Issue 1 January 2018 Abstract Quantity and quality of circulating cell-free DNA (cfDNA) from plasma is highly variable, with frequent contamination of larger, genomic DNA as a consequence [...]
CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]
BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, has named medical oncologist and cancer researcher Glen J. Weiss, M.D., MBA, as Chief Medical Officer. Dr. Weiss will oversee and advance the [...]
November 15, 2017 Circulogene's Chen-Hsiung Yeh, Ph.D., CSO, was recently featured in a new article titled, Cell-Free DNA Drives Liquid Biopsy Testing published by Genetic Engineering & Biotechnology News. "Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics, believes that what makes [...]
